UNSPSC 51343116: Azidothymidine or zidovudine

This classification denotes a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4B9XT59T7S. European Medicines Agency schedules Zidovudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00153MIG. Zidovudine generally arises in the molecular formula C10H13N5O4.

The term ZIDOVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, no. 4, 1987, list 27.) ZIDOVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Azidothymidine or zidovudine bears US NLM identifiers UMLS ID C0043474 and NCI Concept Code C947. SMILES: CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-].

UNSPSC 51343116 Azidothymidine or zidovudine is a Commodity code that reflects state and local government procurement of specialized pharmaceuticals and medical supplies, though recent opportunities posted under this code show substantial mismatch with the nominal product scope. The three state-local opportunities on record involve naloxone and drug deactivation systems (Seminole County, Florida), medical and first aid supplies for emergency response (City of Tampa), and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). These solicitations indicate that the code is being applied to a broader range of pharmaceutical procurement activity — including emergency medical supplies, generic drug programs, and OTC products — rather than specifically targeting antiretroviral agents. The issuing bodies include county health departments, municipal fire departments, and state cooperative purchasing alliances that aggregate demand across participating jurisdictions, reflecting the diversity of end users relying on this taxonomy.

Geographic activity spans Florida, Texas, Minnesota, and Oregon in the most recent postings. The Seminole County opportunity (IFB 60459723LAS, posted June 30, 2026, due July 26, 2023) sought annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems for quarterly delivery with no explicit set-aside designation. The City of Tampa's sealed-bid solicitation (26P00145, due March 13, 2026, estimated $700,000) for medical and first aid supplies serving the Fire Department Rescue Division was designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, proposals due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with 75 percent evaluation weight on price competitiveness and contract terms effective July 1, 2026. These recent postings reflect substantial variance from the code's stated scope, suggesting that the code captures a wider range of pharmaceutical and medical supply procurement than its nominal definition alone would indicate.